Hypertrophic Cardiomyopathy (HCM) Treatment Market Size to Reach USD 31.11 Bn by 2034

Vantage Market Research releases its latest comprehensive report on the ‘Hypertrophic Cardiomyopathy Treatment Market’ with a forecast period of 2025-2034. In 2023, the global Hypertrophic Cardiomyopathy (HCM) treatment market size was USD 1.28 billion, and is calculated at USD 1.33 billionin 2024. The HCM market is projected to reach USD 1.99 billion in 2034, and register a revenue CAGR of 4.1% over the forecast period (2025-2034).

Market Overview:

Global Hypertrophic Cardiomyopathy (HCM) treatment market revenue growth has been moderately steady in the past, but is expected to increase to 4.1% between 2025 and 2034. This projected incline in revenue growth can be attributed to increasing numbers of patients seeking medical support for heart-related symptoms such as chest pain, shortness of breath, and palpitations. This trend is paralleled by advancements in genetic diagnostics and a growing awareness of family medical history and genetic mutations, both of which play a central role in HCM diagnosis.

Current trends, including adoption of preventive healthcare, have led to an increase in early HCM detection and treatment. As patients and healthcare providers prioritize screening for genetic predispositions, diagnostic rates are rising, supported by technological innovations in medical imaging and genetic testing tools. These advancements allow for timely, accurate diagnoses and prompt treatment of hypertrophic cardiomyopathy, encouraging more patients to pursue testing and related treatment options. Factors such as hypertension, global aging global population, and rising obesity rates are further contributing to the prevalence of HCM, and this is highlighting need for continued innovation in treatment and diagnostics.

HCM, which is a genetic heart disorder affecting the sarcomere protein responsible for heart contraction, can result in left ventricular thickening and restricted blood flow, leading to serious symptoms or even remaining asymptomatic. Primary treatment options include beta-blockers and calcium channel blockers, which improve heart function, as well as procedural interventions like alcohol septal ablation and septal myectomy for more severe cases.

Adoption of personalized medicine in HCM care is expanding rapidly, driving demand for therapies tailored to individual genetic profiles. Pharmaceutical companies are partnering with research institutions to develop innovative medications and targeted therapies, facilitated by a favorable reimbursement landscape and regulatory support. This approach has gained particular traction in the US and countries in Europe, where modernized healthcare infrastructure supports early adoption of novel treatments. Leading pharmaceutical firms are leveraging these opportunities by advancing research, securing drug approvals, and introducing more effective therapies.

Focus on early diagnosis and preventive healthcare: is on the rise with more individuals actively seeking medical advice due to family history or genetic risk. Rising focus on preventive care encourages earlier intervention, allowing for timely management and better patient outcomes. Rapid progress in medical technology has made it easier to detect HCM through advanced imaging and diagnostic tools. This increased diagnostic capability leads to higher diagnosis rates and rising awareness in this regard is driving demand for HCM treatments. Also, rising prevalence of risk factors such as hypertension and aging global population are contributing to a larger patient pool at risk for HCM. Rising prevalence of these factors and increasing focus across the healthcare sector to deploy measures and programs to enable meeting rising patient footfalls with age-related conditions and diseases, genetic mutations, heart conditions, and increasing pool of patients seeking preventive treatment and management solutions are key factors supporting growth of the market.

In addition, the trend toward treatments tailored to individual genetic profiles is driving demand for innovative medications in HCM care. Pharmaceutical companies are increasing R&D efforts to develop targeted therapies that address unique genetic underpinnings of hypertrophic cardiomyopathy. This is also expected to support growth of the market. Genetic testing is increasingly becoming part of routine healthcare, particularly in the US and some countries in Europe. This integration supports early detection of HCM and proactive treatment, making HCM management more accessible and effective. Partnerships between pharmaceutical companies and research institutions are encouraging and driving creation of novel HCM treatments. These collaborations are also adding to the intensity of competition in the market, by expanding the range of available treatment options. Improving reimbursement and insurance coverage for HCM therapies are reducing financial barriers for patients are key factors encouraging more individuals to seek treatment. This barrier has been a major restraint or challenge to individuals seeking medical interventions in the past, and emergence of more favorable policies are expected to have a positive impact and support market growth.

Some Key Takeaways:

• North America led in terms of revenue share in 2023, driven largely by high awareness about HCM, robust healthcare infrastructure, and favorable regulatory environment for advanced therapies in the US. 
• Europe market position is supported by revenue contributions from Germany, the UK, and France, where government support for cardiovascular health programs has strengthened HCM diagnosis and treatment rates.
• Asia Pacific Hypertrophic Cardiomyopathy (HCM) treatment market revenue growth is supported majorly by contribution from Japan, China, and India.
• The drug therapy segment is expected to account for largest revenue share among the treatment type segments over the forecast period.
• The myosin inhibitors segment is expected to lead in terms of revenue share among the drug class segments over the forecast period.
• The imaging segment is expected to dominate others among the diagnosis and monitoring segments over the forecast period.
• The hospitals segment is expected to account for largest revenue share among the end-user segments over the forecast period. 
• The competitive landscape of the Hypertrophic Cardiomyopathy (HCM) market is characterized by increasing number of pharmaceutical companies, biotech firms, and diagnostic providers focusing on development of effective HCM treatments. 
• Key players such as Bristol Myers Squibb (BMS), Cytokinetics, Novartis, Sanofi, and Pfizer are focusing on developing and commercializing innovative therapies, particularly targeted drugs like mavacamten (BMS) and aficamten (Cytokinetics.

Company List:

• Bristol Myers Squibb (BMS)
• Cytokinetics, Inc.
• Novartis AG
• Sanofi
• Pfizer Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Amgen Inc.
• Alexion Pharmaceuticals, Inc. (AstraZeneca)
• Takeda Pharmaceutical Company Limited

Recent Developments:

• August 15, 2024: Bristol Myers Squibb Canada (BMS) achieved a significant milestone for patients in Quebec and Alberta with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) who qualify for federal government coverage through the Non-Insured Health Benefits (NIHB) Program. CAMZYOS (mavacamten capsules), the first oral cardiac myosin inhibitor approved in Canada for managing oHCM, has now been added to the Régie de l'assurance maladie du Québec (RAMQ) List of Medications, Alberta’s Drug Benefits List, and the NIHB drug plan under Indigenous Services Canada. This inclusion offers coverage to patients who meet specific criteria. CAMZYOS is uniquely positioned as the only Health Canada-approved myosin inhibitor with reversible action, specifically aimed at treating symptomatic obstructive HCM in adults classified as New York Heart Association (NYHA) Class II-III. By targeting the underlying cause of oHCM, this oral therapy provides a non-invasive treatment option that addresses a key gap in care for individuals with this challenging cardiac condition, offering an alternative to more invasive interventions for eligible patients.
• January 25, 2024: Cytokinetics, Inc. shared new data at CMR 2024 showcasing the effects of aficamten on cardiac structure, function, and fibrosis in patients with hypertrophic cardiomyopathy. The data was derived from the FOREST-HCM study (Follow-up, Open-Label, Research Evaluation of Sustained Treatment with Aficamten in HCM), which is an open-label extension trial examining aficamten’s impact in this patient population. The study builds on previous research by assessing aficamten’s potential benefits in enhancing exercise tolerance and alleviating HCM symptoms, as well as its effects on heart structure and functional capacity over an extended period. Cytokinetics’ aficamten development program aims to confirm the drug’s potential in reducing the symptomatic and structural challenges of HCM, with a focus on improving patient quality of life through sustained therapy.
• August 15, 2023: Viz.ai announced securing a De Novo approval by the U.S. Food and Drug Administration (FDA) for its Viz HCM module, which is a hypertrophic cardiomyopathy artificial intelligence detection algorithm. This approval required creation of a new regulatory category for cardiovascular machine learning-based notification software. Deployment of the algorithm is funded by a multi-year agreement with Bristol Myers Squibb announced in March. Viz HCM, which is integrated into the Viz.ai Platform, enables more patients with suspected HCM to be identified earlier using AI and triaged for diagnosis and further evaluation.

Global Hypertrophic Cardiomyopathy (HCM) Treatment Market Segmentation:

By Treatment Type

• Drug Therapy
• Surgical Procedures
• Non-Surgical Procedures 
• Lifestyle and Non-Pharmacological Management

By Drug Class

• Beta Blockers
• Calcium Channel Blockers
• Antiarrhythmic Drugs
• Myosin Inhibitors

By Diagnosis & Monitoring

• Genetic Testing
• Imaging (Echocardiography, MRI)
• Electrocardiogram (ECG)
• Blood Tests

By End User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers
• Homecare Settings

Regional Segmentation: 

North America

• United States
• Canada
• Mexico

Europe

• Germany
• United Kingdom
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Rest of Latin America 

Middle East & Africa

• Saudi Arabia
• South Africa
• United Arab Emirates
• Israel
• Rest of MEA